In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting
The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
However, regulatory and financial issues will shape when and where this happens
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data
Findings call for a change in tumour categorisation, from a cell-of-origin to a tumour microenvironment-associated holistic approach
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.